Balanced news tone
News Sentiment
IDYA sentiment intelligence
Ideaya Biosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
83/100 classification confidence.
directly relevant articles
high-authority source matches
-1.8% over one week, +27.6% over four weeks, trend inactive, and near fair-value range.
Ideaya Biosciences chief accounting officer sells $382,130 in stock
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
IDEAYA Biosciences (IDYA) First Patient Enrollment Puts Valuation Back In Focus
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 07:00
- Source
- simplywall.st
IDEAYA Biosciences Elects CEO Yujiro Hata as Chairman
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 10:50
- Source
- MT Newswires
IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 10:00
- Source
- PR Newswire
Cancer research CEO Yujiro Hata now also chairs IDEAYA board
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 07:00
- Source
- Stock Titan
IDEAYA Biosciences' Phase 1 Clinical Trial of Lung, Pancreatic Cancer Treatment Enrolls First Patient
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 11:59
- Source
- MT Newswires
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 10:00
- Source
- PR Newswire
Ideaya Biosciences (IDYA) Forms Clinical Partnership With Roche for IDE892 Efficacy Study
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 11 Jun 2026 10:20
- Source
- Insider Monkey
IDEAYA Biosciences: 'Strong Buy' On Darovasertib NDA Filing Submission Completion H2 2026
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 11 Jun 2026 07:00
- Source
- Seeking Alpha
Ideaya Biosciences Closes $345 Million Public Offering
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jun 2026 20:31
- Source
- MT Newswires
IDEAYA Biosciences (NASDAQ: IDYA) raises $323.6M via stock and pre-funded warrants
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 10 Jun 2026 07:00
- Source
- Stock Titan
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jun 2026 07:00
- Source
- PR Newswire
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2026 07:00
- Source
- BioSpace
IDEAYA sets $27 price in $300M stock and warrant sale to investors
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jun 2026 07:00
- Source
- Stock Titan
Biotech IDEAYA grants new hires 221,000 options over 4 years
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 May 2026 07:00
- Source
- Stock Titan
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
IDEAYA Biosciences (IDYA) Persistent Losses Challenge Bullish High Revenue Growth Narratives
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 06 May 2026 07:00
- Source
- simplywall.st
Is IDEAYA Biosciences, Inc. (IDYA) A Good Stock To Buy Now?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 03 May 2026 07:00
- Source
- Market source
Five new IDEAYA hires receive stock options at $29.10 a share
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 May 2026 07:00
- Source
- Stock Titan
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
IDEAYA And AstraZeneca Collaboration Adds New Dimension To IDE849 And Valuation
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Apr 2026 07:00
- Source
- simplywall.st
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Ideaya Biosciences: Stock Buoyant On Good mUM Data - But Approval Not A Formality
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 13 Apr 2026 07:00
- Source
- Seeking Alpha
Why Is Ideaya Biosciences (IDYA) Stock Surging Over 20% Overnight?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Apr 2026 07:00
- Source
- Stocktwits
IDEAYA to reveal April 13 trial data in metastatic uveal melanoma
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Apr 2026 07:00
- Source
- Stock Titan
A Look At IDEAYA Biosciences (IDYA) Valuation After New DLL3 Combo Trial Progress And Early Responses
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Apr 2026 07:00
- Source
- Market source
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Ideaya Biosciences stock maintained at Outperform by Mizuho on trial timing
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 23 Mar 2026 07:00
- Source
- Investing.com